Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Disruption of peroxisome proliferator-activated receptor γ coactivator (PGC)-1α reverts key features of the neoplastic phenotype of glioma cells.

Bruns I, Sauer B, Burger MC, Eriksson J, Hofmann U, Braun Y, Harter PN, Luger AL, Ronellenfitsch MW, Steinbach JP, Rieger J.

J Biol Chem. 2019 Mar 1;294(9):3037-3050. doi: 10.1074/jbc.RA118.006993. Epub 2018 Dec 21.

PMID:
30578297
2.

Gene Suppression of Transketolase-Like Protein 1 (TKTL1) Sensitizes Glioma Cells to Hypoxia and Ionizing Radiation.

Heller S, Maurer GD, Wanka C, Hofmann U, Luger AL, Bruns I, Steinbach JP, Rieger J.

Int J Mol Sci. 2018 Jul 25;19(8). pii: E2168. doi: 10.3390/ijms19082168.

3.

Mammalian target of rapamycin complex 1 activation sensitizes human glioma cells to hypoxia-induced cell death.

Thiepold AL, Lorenz NI, Foltyn M, Engel AL, Divé I, Urban H, Heller S, Bruns I, Hofmann U, Dröse S, Harter PN, Mittelbronn M, Steinbach JP, Ronellenfitsch MW.

Brain. 2017 Oct 1;140(10):2623-2638. doi: 10.1093/brain/awx196.

PMID:
28969371
4.

Lenalidomide consolidation treatment in patients with multiple myeloma suppresses myelopoieses but spares erythropoiesis.

Wilk CM, Heinzler N, Boquoi A, Cadeddu RP, Strapatsas T, Dienst A, Majidi F, Deenen R, Bruns I, Schroeder T, Köhrer K, Haas R, Kobbe G, Fenk R.

Int J Cancer. 2016 Nov 15;139(10):2343-52. doi: 10.1002/ijc.30257. Epub 2016 Aug 13.

5.

Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy.

Zohren F, Bruns I, Pechtel S, Schroeder T, Fenk R, Czibere A, Maschmeyer G, Kofahl-Krause D, Niederle N, Heil G, Losem C, Welslau M, Brugger W, Germing U, Kronenwett R, Barth J, Rummel MJ, Haas R, Kobbe G.

Blood. 2015 Sep 17;126(12):1407-14. doi: 10.1182/blood-2015-03-630012. Epub 2015 Aug 3.

PMID:
26239087
6.

Megakaryocytes regulate hematopoietic stem cell quiescence through CXCL4 secretion.

Bruns I, Lucas D, Pinho S, Ahmed J, Lambert MP, Kunisaki Y, Scheiermann C, Schiff L, Poncz M, Bergman A, Frenette PS.

Nat Med. 2014 Nov;20(11):1315-20. doi: 10.1038/nm.3707. Epub 2014 Oct 19.

7.

[7th revision of the declaration of Helsinki: more than a recommendation?].

Krockenberger K, Bruns I, Ziegler A.

Dtsch Med Wochenschr. 2014 Feb;139(8):367-8. doi: 10.1055/s-0033-1360048. Epub 2014 Jan 20. German. No abstract available.

PMID:
24446077
8.

Arteriolar niches maintain haematopoietic stem cell quiescence.

Kunisaki Y, Bruns I, Scheiermann C, Ahmed J, Pinho S, Zhang D, Mizoguchi T, Wei Q, Lucas D, Ito K, Mar JC, Bergman A, Frenette PS.

Nature. 2013 Oct 31;502(7473):637-43. doi: 10.1038/nature12612. Epub 2013 Oct 9.

9.

Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells.

Geyh S, Oz S, Cadeddu RP, Fröbel J, Brückner B, Kündgen A, Fenk R, Bruns I, Zilkens C, Hermsen D, Gattermann N, Kobbe G, Germing U, Lyko F, Haas R, Schroeder T.

Leukemia. 2013 Sep;27(9):1841-51. doi: 10.1038/leu.2013.193. Epub 2013 Mar 29.

PMID:
23797473
10.

PDGFRα and CD51 mark human nestin+ sphere-forming mesenchymal stem cells capable of hematopoietic progenitor cell expansion.

Pinho S, Lacombe J, Hanoun M, Mizoguchi T, Bruns I, Kunisaki Y, Frenette PS.

J Exp Med. 2013 Jul 1;210(7):1351-67. doi: 10.1084/jem.20122252. Epub 2013 Jun 17.

11.

The tissue inhibitor of metalloproteinases-1 improves migration and adhesion of hematopoietic stem and progenitor cells.

Wilk CM, Schildberg FA, Lauterbach MA, Cadeddu RP, Fröbel J, Westphal V, Tolba RH, Hell SW, Czibere A, Bruns I, Haas R.

Exp Hematol. 2013 Sep;41(9):823-831.e2. doi: 10.1016/j.exphem.2013.04.010. Epub 2013 May 6.

PMID:
23660069
12.

Chemotherapy-induced bone marrow nerve injury impairs hematopoietic regeneration.

Lucas D, Scheiermann C, Chow A, Kunisaki Y, Bruns I, Barrick C, Tessarollo L, Frenette PS.

Nat Med. 2013 Jun;19(6):695-703. doi: 10.1038/nm.3155. Epub 2013 May 5.

13.

Platelet proteome analysis reveals integrin-dependent aggregation defects in patients with myelodysplastic syndromes.

Fröbel J, Cadeddu RP, Hartwig S, Bruns I, Wilk CM, Kündgen A, Fischer JC, Schroeder T, Steidl UG, Germing U, Lehr S, Haas R, Czibere A.

Mol Cell Proteomics. 2013 May;12(5):1272-80. doi: 10.1074/mcp.M112.023168. Epub 2013 Feb 4.

14.

Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation.

Schroeder T, Czibere A, Platzbecker U, Bug G, Uharek L, Luft T, Giagounidis A, Zohren F, Bruns I, Wolschke C, Rieger K, Fenk R, Germing U, Haas R, Kröger N, Kobbe G.

Leukemia. 2013 Jun;27(6):1229-35. doi: 10.1038/leu.2013.7. Epub 2013 Jan 14.

PMID:
23314834
15.

Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cells.

Bruns I, Cadeddu RP, Brueckmann I, Fröbel J, Geyh S, Büst S, Fischer JC, Roels F, Wilk CM, Schildberg FA, Hünerlitürkoglu AN, Zilkens C, Jäger M, Steidl U, Zohren F, Fenk R, Kobbe G, Brors B, Czibere A, Schroeder T, Trumpp A, Haas R.

Blood. 2012 Sep 27;120(13):2620-30. Epub 2012 Apr 18.

16.

Norepinephrine reuptake inhibition promotes mobilization in mice: potential impact to rescue low stem cell yields.

Lucas D, Bruns I, Battista M, Mendez-Ferrer S, Magnon C, Kunisaki Y, Frenette PS.

Blood. 2012 Apr 26;119(17):3962-5. doi: 10.1182/blood-2011-07-367102. Epub 2012 Mar 14.

17.

Natalizumab and impedance of the homing of CD34+ hematopoietic progenitors.

Saure C, Warnke C, Zohren F, Schroeder T, Bruns I, Cadeddu RP, Weigelt C, Fischer U, Kobbe G, Hartung HP, Adams O, Kieseier BC, Haas R.

Arch Neurol. 2011 Nov;68(11):1428-31. doi: 10.1001/archneurol.2011.238.

PMID:
22084125
18.

Secondary primary malignancies in patients with multiple myeloma treated with high-dose chemotherapy and autologous blood stem cell transplantation.

Fenk R, Neubauer F, Bruns I, Schröder T, Germing U, Haas R, Kobbe G.

Br J Haematol. 2012 Mar;156(5):683-6. doi: 10.1111/j.1365-2141.2011.08905.x. Epub 2011 Nov 3. No abstract available.

PMID:
22050384
19.

Therapy-related myeloid neoplasms following treatment with radioiodine.

Schroeder T, Kuendgen A, Kayser S, Kröger N, Braulke F, Platzbecker U, Klärner V, Zohren F, Haase D, Stadler M, Schlenk R, Czibere AG, Bruns I, Fenk R, Gattermann N, Haas R, Kobbe G, Germing U.

Haematologica. 2012 Feb;97(2):206-12. doi: 10.3324/haematol.2011.049114. Epub 2011 Oct 11.

20.

Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.

Saure C, Schroeder T, Zohren F, Groten A, Bruns I, Czibere A, Galonska L, Kondakci M, Weigelt C, Fenk R, Germing U, Haas R, Kobbe G.

Biol Blood Marrow Transplant. 2012 Mar;18(3):466-72. doi: 10.1016/j.bbmt.2011.09.006. Epub 2011 Sep 29.

21.

The level of minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood stem cell transplantation is an independent predictive parameter.

Korthals M, Sehnke N, Kronenwett R, Bruns I, Mau J, Zohren F, Haas R, Kobbe G, Fenk R.

Biol Blood Marrow Transplant. 2012 Mar;18(3):423-431.e3. doi: 10.1016/j.bbmt.2011.07.002. Epub 2011 Jul 13.

22.

The non-steroidal anti-inflammatory drugs Sulindac sulfide and Diclofenac induce apoptosis and differentiation in human acute myeloid leukemia cells through an AP-1 dependent pathway.

Singh R, Cadeddu RP, Fröbel J, Wilk CM, Bruns I, Zerbini LF, Prenzel T, Hartwig S, Brünnert D, Schroeder T, Lehr S, Haas R, Czibere A.

Apoptosis. 2011 Sep;16(9):889-901. doi: 10.1007/s10495-011-0624-y.

PMID:
21739277
23.

The novel compound OSI-461 induces apoptosis and growth arrest in human acute myeloid leukemia cells.

Singh R, Fröbel J, Cadeddu RP, Bruns I, Schroeder T, Brünnert D, Wilk CM, Zerbini LF, Haas R, Czibere A.

Ann Hematol. 2012 Feb;91(2):173-81. doi: 10.1007/s00277-011-1282-4. Epub 2011 Jun 30.

PMID:
21717102
24.

Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation.

Fenk R, Liese V, Neubauer F, Bruns I, Kondakci M, Balleisen S, Saure C, Schröder T, Haas R, Kobbe G.

Leuk Lymphoma. 2011 Aug;52(8):1455-62. doi: 10.3109/10428194.2011.575967. Epub 2011 Jun 10.

PMID:
21657961
25.

High-dose therapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma.

Haas R, Bruns I, Kobbe G, Fenk R.

Recent Results Cancer Res. 2011;183:207-38. doi: 10.1007/978-3-540-85772-3_10. Review.

PMID:
21509687
26.

Esophageal cancer proliferation is mediated by cytochrome P450 2C9 (CYP2C9).

Schmelzle M, Dizdar L, Matthaei H, Baldus SE, Wolters J, Lindenlauf N, Bruns I, Cadeddu RP, Kröpil F, Topp SA, Schulte am Esch J 2nd, Eisenberger CF, Knoefel WT, Stoecklein NH.

Prostaglandins Other Lipid Mediat. 2011 Feb;94(1-2):25-33. doi: 10.1016/j.prostaglandins.2010.12.001. Epub 2010 Dec 15.

PMID:
21167292
27.

Is standardised vaginal sacrospinous ligament fixation a safe teaching procedure for residents?

Sauerwald A, Bruns I, Peveling B, Brunke H, Wolff F.

Int Urogynecol J. 2011 Mar;22(3):293-8. doi: 10.1007/s00192-010-1341-8. Epub 2010 Dec 10.

PMID:
21153470
28.

[The Coordinating Centers for Clinical Trials (KKS) and the KKS Network: competence for clinical research].

Ohmann C, Bruns I, Wolff S.

Onkologie. 2010;33 Suppl 7:11-5. doi: 10.1159/000319734. Epub 2010 Sep 16. German.

PMID:
20926908
29.

Sorafenib treatment in 13 patients with acute myeloid leukemia and activating FLT3 mutations in combination with chemotherapy or as monotherapy.

Schroeder T, Zohren F, Saure C, Bruns I, Czibere A, Safaian NN, Fenk R, Haas R, Kobbe G.

Acta Haematol. 2010;124(3):153-9. doi: 10.1159/000320173. Epub 2010 Oct 11. No abstract available.

PMID:
20938170
30.

Tacrolimus and mycofenolate mofetil as GvHD prophylaxis following nonmyeloablative conditioning and unrelated hematopoietic SCT for adult patients with advanced hematologic diseases.

Zohren F, Schroeder T, Czibere A, Fenk R, Bruns I, Kondakci M, Saure C, Haas R, Kobbe G.

Bone Marrow Transplant. 2011 May;46(5):747-55. doi: 10.1038/bmt.2010.167. Epub 2010 Jul 26.

PMID:
20661230
31.

The Mexican way: a feasible approach to avoid DMSO toxicity.

Schroeder T, Fenk R, Saure C, Czibere A, Bruns I, Zohren F, Haas R, Kobbe G.

Bone Marrow Transplant. 2011 Mar;46(3):469-71. doi: 10.1038/bmt.2010.140. Epub 2010 Jun 14. No abstract available.

PMID:
20548338
32.

A 3-day short course of palifermin before HDT reduces toxicity and need for supportive care after autologous blood stem-cell transplantation in patients with multiple myeloma.

Kobbe G, Bruns I, Schroeder T, Czibere A, Warnecke J, Hieronimus N, Safaian N, Kondakci M, Saure C, Germing U, Haas R, Fenk R.

Ann Oncol. 2010 Sep;21(9):1898-904. doi: 10.1093/annonc/mdq059. Epub 2010 Mar 16.

PMID:
20233744
33.

Bendamustine in patients with relapsed or refractory multiple myeloma.

Michael M, Bruns I, Bölke E, Zohren F, Czibere A, Safaian NN, Neumann F, Haas R, Kobbe G, Fenk R.

Eur J Med Res. 2010 Jan 29;15(1):13-9.

34.

Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells.

Biernacki MA, Marina O, Zhang W, Liu F, Bruns I, Cai A, Neuberg D, Canning CM, Alyea EP, Soiffer RJ, Brusic V, Ritz J, Wu CJ.

Cancer Res. 2010 Feb 1;70(3):906-15. doi: 10.1158/0008-5472.CAN-09-2303. Epub 2010 Jan 26.

35.

5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis.

Czibere A, Bruns I, Kröger N, Platzbecker U, Lind J, Zohren F, Fenk R, Germing U, Schröder T, Gräf T, Haas R, Kobbe G.

Bone Marrow Transplant. 2010 May;45(5):872-6. doi: 10.1038/bmt.2009.266. Epub 2009 Oct 12.

PMID:
19820729
36.

Low RPS14 expression is common in myelodysplastic syndromes without 5q- aberration and defines a subgroup of patients with prolonged survival.

Czibere A, Bruns I, Junge B, Singh R, Kobbe G, Haas R, Germing U.

Haematologica. 2009 Oct;94(10):1453-5. doi: 10.3324/haematol.2009.008508.

37.

Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome.

Will B, Kawahara M, Luciano JP, Bruns I, Parekh S, Erickson-Miller CL, Aivado MA, Verma A, Steidl U.

Blood. 2009 Oct 29;114(18):3899-908. doi: 10.1182/blood-2009-04-219493. Epub 2009 Aug 26.

38.

Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia.

Zohren F, Czibere A, Bruns I, Fenk R, Schroeder T, Gräf T, Haas R, Kobbe G.

Bone Marrow Transplant. 2009 Dec;44(12):785-92. doi: 10.1038/bmt.2009.83. Epub 2009 May 11.

PMID:
19430496
39.

Pegfilgrastim for PBSC mobilization and autologous haematopoietic SCT.

Kobbe G, Bruns I, Fenk R, Czibere A, Haas R.

Bone Marrow Transplant. 2009 May;43(9):669-77. doi: 10.1038/bmt.2009.59. Epub 2009 Mar 23. Review.

PMID:
19308043
40.

[The Coordinating Centres for Clinical Trials Network. Objectives and significance for research sites].

Bruns I, Maier-Lenz H, Wolff S.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2009 Apr;52(4):451-8. doi: 10.1007/s00103-009-0828-2. German.

PMID:
19277472
41.

The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence.

Bruns I, Czibere A, Fischer JC, Roels F, Cadeddu RP, Buest S, Bruennert D, Huenerlituerkoglu AN, Stoecklein NH, Singh R, Zerbini LF, Jäger M, Kobbe G, Gattermann N, Kronenwett R, Brors B, Haas R.

Leukemia. 2009 May;23(5):892-9. doi: 10.1038/leu.2008.392. Epub 2009 Jan 22.

PMID:
19158832
42.

Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy.

Bruennert D, Czibere A, Bruns I, Kronenwett R, Gattermann N, Haas R, Neumann F.

Leukemia. 2009 May;23(5):983-5. doi: 10.1038/leu.2008.337. Epub 2008 Dec 4. No abstract available.

PMID:
19052557
43.

Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia.

Safaian NN, Czibere A, Bruns I, Fenk R, Reinecke P, Dienst A, Haas R, Kobbe G.

Leuk Res. 2009 Feb;33(2):348-50. doi: 10.1016/j.leukres.2008.04.017. Epub 2008 Jun 24.

PMID:
18573526
44.

Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor.

Bruns I, Steidl U, Fischer JC, Czibere A, Kobbe G, Raschke S, Singh R, Fenk R, Rosskopf M, Pechtel S, von Haeseler A, Wernet P, Tenen DG, Haas R, Kronenwett R.

Haematologica. 2008 Mar;93(3):347-55. doi: 10.3324/haematol.12081. Epub 2008 Feb 11.

45.
46.

The sepsis-related Organ Failure Assessment (SOFA) score is predictive for survival of patients admitted to the intensive care unit following allogeneic blood stem cell transplantation.

Neumann F, Lobitz O, Fenk R, Bruns I, Köstering M, Steiner S, Hennersdorf M, Kelm M, Strauer BE, Germing U, Hinke A, Haas R, Kobbe G.

Ann Hematol. 2008 Apr;87(4):299-304. doi: 10.1007/s00277-008-0440-9. Epub 2008 Jan 25.

PMID:
18219487
47.

Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma.

Fenk R, Michael M, Zohren F, Graef T, Czibere A, Bruns I, Neumann F, Fenk B, Haas R, Kobbe G.

Leuk Lymphoma. 2007 Dec;48(12):2345-51.

PMID:
18067009
48.

Treatment of severe hemorrhagic cystitis after allogeneic stem cell transplantation with palifermin, a recombinant human keratinocyte growth factor.

Czibere A, Bruns I, Graef T, Fenk R, Zohren F, Safaian N, Mueller M, Haas R, Kobbe G.

Biol Blood Marrow Transplant. 2007 Jul;13(7):872-4. Epub 2007 May 23. No abstract available.

49.

Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase.

Diaz-Blanco E, Bruns I, Neumann F, Fischer JC, Graef T, Rosskopf M, Brors B, Pechtel S, Bork S, Koch A, Baer A, Rohr UP, Kobbe G, von Haeseler A, Gattermann N, Haas R, Kronenwett R.

Leukemia. 2007 Mar;21(3):494-504. Epub 2007 Jan 25.

PMID:
17252012
50.

Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells.

Steidl U, Rosenbauer F, Verhaak RG, Gu X, Ebralidze A, Otu HH, Klippel S, Steidl C, Bruns I, Costa DB, Wagner K, Aivado M, Kobbe G, Valk PJ, Passegué E, Libermann TA, Delwel R, Tenen DG.

Nat Genet. 2006 Nov;38(11):1269-77. Epub 2006 Oct 15.

PMID:
17041602

Supplemental Content

Support Center